Related references
Note: Only part of the references are listed.Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella
Wilson Lim et al.
MEDICAL MYCOLOGY (2022)
The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma
Mickey Konings et al.
PLOS NEGLECTED TROPICAL DISEASES (2021)
Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim
Wilson Lim et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Mycetoma epidemiology, diagnosis management, and outcome in three hospital centres in Senegal from 2008 to 2018
Doudou Sow et al.
PLOS ONE (2020)
Proteomic analysis of the processes leading to Madurella mycetomatis grain formation in Galleria mellonella larvae
Gerard Sheehan et al.
PLOS NEGLECTED TROPICAL DISEASES (2020)
In Vitro Activities of Ravuconazole and Isavuconazole against Dematiaceous Fungi
Hailin Zheng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects
Lamis Y. M. Elkheir et al.
PLOS NEGLECTED TROPICAL DISEASES (2020)
Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery
Martina Maccesi et al.
PARASITES & VECTORS (2019)
Screening the Pathogen Box for Identification of New Chemical Agents with Anti-Fasciola hepatica Activity
Claudia Machicado et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Similarities and differences in the biotransformation and transcriptomic responses of Caenorhabditis elegans and Haemonchus contortus to five different benzimidazole drugs
S. J. Stasiuk et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2019)
Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis
Wendy Kloezen et al.
MEDICAL MYCOLOGY (2018)
Double Edge Sword Behavior of Carbendazim: A Potent Fungicide With Anticancer Therapeutic Properties
Karan Goyal et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2018)
Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus
Saskia du Pre et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma
Wilson Lim et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
Azole-induced cell wall carbohydrate patches kill Aspergillus fumigatus
Bernadette Geissel et al.
NATURE COMMUNICATIONS (2018)
Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
Nilambra Dogra et al.
SCIENTIFIC REPORTS (2018)
Mycetoma: a unique neglected tropical disease
Eduard E. Zijlstra et al.
LANCET INFECTIOUS DISEASES (2016)
Mechanism of Action of the Benzimidazole Fungicide on Fusarium graminearum: Interfering with Polymerization of Monomeric Tubulin But Not Polymerized Microtubule
Yujun Zhou et al.
PHYTOPATHOLOGY (2016)
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Jason D. Oliver et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals
Sarah Abdalla Ahmed et al.
MEDICAL MYCOLOGY (2015)
A Madurella mycetomatis Grain Model in Galleria mellonella Larvae
Wendy Kloezen et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Madurella mycetomatis Is Highly Susceptible to Ravuconazole
Sarah Abdalla Ahmed et al.
PLOS NEGLECTED TROPICAL DISEASES (2014)
Mycetoma Medical Therapy
Oliverio Welsh et al.
PLOS NEGLECTED TROPICAL DISEASES (2014)
Global Burden of Human Mycetoma: A Systematic Review and Meta-analysis
Wendy W. J. van de Sande
PLOS NEGLECTED TROPICAL DISEASES (2013)
In Vitro Antifungal Activity of Isavuconazole against Madurella mycetomatis
Wendy Kloezen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Actinomycetoma and advances in its treatment
Oliverio Welsh et al.
CLINICS IN DERMATOLOGY (2012)
Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan
Hagir A. M. Zein et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2012)
The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis
A. H. Fahal et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2011)
Use of Antifungal Combination Therapy: Agents, Order, and Timing
Melissa D. Johnson et al.
CURRENT FUNGAL INFECTION REPORTS (2010)
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease
Leah E. Cowen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi
M Cuenca-Estrella et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Genotyping of Madurella mycetomatis by selective amplification of restriction fragments (amplified fragment length polymorphism) and subtype correlation with geographical origin and lesion size
WWJ van de Sande et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi
GM González et al.
MEDICAL MYCOLOGY (2005)
Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method
WWJ van de Sande et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates
M Cuenca-Estrella et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization
C Serena et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi
DJ Diekema et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
T Yamazumi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
